LAHORE: Only three percent of cancer patients in Pakistan are diagnosed at an early and curable stage, while 22 percent are ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, said: “This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

Nearly 75 per cent of cancer patients in Pakistan are diagnosed when the disease has advanced to stage three or four, leaving limited treatment options and poor chances of survival, leading ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in ...

THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment was given the green light to be ...